|
LAUSANNE, Switzerland, April 1, 2019 /PRNewswire/ -- Debiopharm, (www.debiopharm.com/debiopharm-international/) a global biopharmaceutical company based in Switzerland, today announced data releases on 3 investigational products including pre-clinical results of Debio 0123 (Selective WEE1 inhibitor), diagnostic molecular screening for Debio 1347 (FGFR inhibitor) and clinical exploratory results for Debio 1143 (IAP1 inhibitor) at the 2019 Annual AACR meeting in Atlanta, Georgia. These abstract presentations are part of Debiopharm's ongoing oncology programs to investigate the anti-tumor activity and toxicity profile of innovative compounds aimed at treating a broad variety of cancer types.
"These results from our multiple ongoing oncology programs are giving us more insight into the potential of integrating specialized, targeted compounds into current therapeutic strategies."
- Gregoire Vuagniaux, Director of Translational Pharmacology, Debiopharm International SA
AACR 2019 Abstract Presentations
|
Compound
|
Title
|
Date and Time
|
N°
|
|
Debio 0123
|
Antitumor activity of the novel oral highly
selective Wee1 inhibitor Debio 0123
|
Tue, April 2nd,
1:00-5:00pm
|
#4423
|
|
Debio 1143
|
Open-label, exploratory pre-operative window-
of-opportunity trial to investigate the pharmacokinetics
and pharmacodynamics of the SMAC mimetic Debio
1143 in patients with resectable squamous cell
carcinoma of the head and neck
|
Wed, April 3rd,
8:00-12:00pm
|
#5001
|
|
Debio 1347
|
Molecular screening of patients with FGFR
alterations for a phase 1 (ph1) study with the
selective FGFR inhibitor (FGFRi) DEBIO 1347
|
Wed, April 3rd,
8:00-12:00pm
Section 19
|
#4881
|
Debiopharm International's commitment to cancer patients
Debiopharm International SA aims to develop innovative therapies that target high unmet medical needs in oncology. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds for in-licensing and clinical development and then select large pharmaceutical commercialization partners to maximize patient access across the globe.
Find out about our currently clinical trials at patients.debiopharm.com
Visit us www.debiopharm.com/debiopharm-international/
Follow us @DebiopharmNews at twitter.com/DebiopharmNews
Debiopharm International SA Contact
Dawn Haughton
Communication Manager
211923@email4pr.com
Tel: +41 (0)21 321 01 11
____________________
1 IAP= Inhibitor of Apoptosis Proteins
 View original content:http://www.prnewswire.com/news-releases/debiopharm-releases-results-of-3-key-oncology-compound-programs-at-the-2019-american-association-for-cancer-research-aacr-conference-in-atlanta-ga-300821033.html
SOURCE Debiopharm International SA
|
